How should I evaluate and manage a patient with a low white blood cell count (neutropenia)?

Evaluation and Management of Low White Blood Cell Count (Neutropenia)

Calculate the Absolute Neutrophil Count (ANC) Immediately

The first step is to calculate the ANC from the WBC count and differential: ANC = WBC × (% neutrophils + % bands) ÷ 100. 1

• ANC ≥1.5 × 10⁹/L: Normal, no neutropenia 1
• ANC 1.0–1.5 × 10⁹/L: Mild neutropenia 1
• ANC 0.5–1.0 × 10⁹/L: Moderate neutropenia 1
• ANC <0.5 × 10⁹/L: Severe neutropenia—this is the critical threshold that triggers immediate action 1, 2
• ANC <0.1 × 10⁹/L: Profound neutropenia—highest risk category 1

Assess for Fever Immediately (If ANC <0.5 × 10⁹/L)

Febrile neutropenia is a medical emergency requiring empiric broad-spectrum antibiotics within 2 hours. 3, 2

• Fever is defined as: single oral temperature ≥38.3°C (101°F) OR temperature ≥38.0°C (100.4°F) sustained for ≥1 hour 2, 1
• If fever is present with ANC <0.5 × 10⁹/L: proceed immediately to febrile neutropenia protocol (see below) 3, 2
• If afebrile with ANC <0.5 × 10⁹/L: proceed to risk stratification for prophylaxis 1

---

Management Algorithm Based on ANC Level

ANC 1.0–1.5 × 10⁹/L (Mild Neutropenia)

For asymptomatic patients with mild neutropenia, repeat CBC with differential in 2–4 weeks to determine if this is transient or chronic. 1

• No antimicrobial prophylaxis is needed at this level 1
• Monitor for symptoms suggesting infection (fever, chills, sore throat), autoimmune disease, or hematologic malignancy 1
• Review medication list for drugs that can cause neutropenia: propylthiouracil, carbamazepine, trimethoprim-sulfamethoxazole, β-lactam antibiotics, clozapine, vancomycin, valproic acid 4, 5
• If the patient is receiving chemotherapy or immunosuppressive therapy, even mild neutropenia warrants closer monitoring and potentially dose adjustments 1
• If fever develops (>38.5°C for >1 hour), immediate evaluation and empiric broad-spectrum antibiotics are necessary 1

ANC 0.5–1.0 × 10⁹/L (Moderate Neutropenia)

Evaluate underlying causes: obtain medication history, assess for autoimmune disease, consider bone marrow biopsy if etiology is unclear. 1

• Hold or adjust causative medications if identified 1
• Daily clinical assessment and CBC monitoring until ANC ≥0.5 × 10⁹/L 1
• No routine antimicrobial prophylaxis unless the patient is high-risk (see below) 1
• Educate the patient to monitor temperature every 4–6 hours and seek immediate care if fever develops 1

ANC <0.5 × 10⁹/L (Severe Neutropenia) – AFEBRILE

Risk-stratify the patient to determine if prophylactic antimicrobials are indicated. 3, 1

High-Risk Criteria (Any of the Following):

• Expected prolonged neutropenia >7 days 3, 1
• ANC <0.1 × 10⁹/L (profound neutropenia) 1
• Underlying hematologic malignancy 3, 1
• Allogeneic hematopoietic stem-cell transplant 1
• Significant mucositis or other serious comorbidities 3
• MASCC score <21 3

High-Risk Afebrile Management:

Initiate fluoroquinolone prophylaxis immediately and continue until ANC >0.5 × 10⁹/L. 1

• Levofloxacin 500 mg PO daily (preferred, especially if mucositis risk is present) 1
• Ciprofloxacin 500 mg PO daily (acceptable alternative) 1
• Additional prophylaxis per NCCN guidelines: 1
  • Fluconazole 400 mg PO daily (antifungal; start at anticipated nadir, stop when ANC >1.0 × 10⁹/L)
  • Trimethoprim-sulfamethoxazole double-strength 1 tablet three times weekly (PCP prophylaxis; continue ≥6 months or until CD4 >200 cells/mm³)
  • Acyclovir 400 mg PO BID or valacyclovir 500 mg PO BID (viral prophylaxis)
• Monitor temperature every 4–6 hours and daily CBC with differential 1
• Educate the patient to seek immediate care if fever develops 1

Low-Risk Criteria (All of the Following):

• Expected brief neutropenia <7 days 3, 1
• MASCC score ≥21 3
• No significant comorbidities 3
• Hemodynamically stable 3

Low-Risk Afebrile Management:

Routine antibacterial prophylaxis is NOT recommended. 1

• Monitor temperature regularly and educate the patient to seek immediate care if fever develops 1
• Daily CBC with differential until ANC recovery 1

---

Management of Febrile Neutropenia (ANC <0.5 × 10⁹/L + Fever)

Febrile neutropenia is a medical emergency; empiric broad-spectrum antibiotics MUST be started within 2 hours of fever onset. 3, 2, 1

Immediate Actions (Within 2 Hours):

1. Obtain cultures BEFORE antibiotics: two sets of blood cultures from separate sites (peripheral and any central line), urine culture, chest radiograph, and cultures from any suspected infection foci 3, 2
2. Start IV antipseudomonal β-lactam immediately: 3, 2
   • Cefepime 2 g IV every 8 hours (preferred) 3, 2
   • Alternatives: ceftazidime, meropenem, imipenem, or piperacillin-tazobactam 3, 2
3. Add vancomycin ONLY if any of the following are present: 3
   • Suspected catheter-related infection
   • Hemodynamic instability
   • Known MRSA colonization
   • Skin/soft-tissue infection
   • Severe mucositis

Duration of Therapy:

Continue broad-spectrum antibiotics until ANC >0.5 × 10⁹/L for at least two consecutive days AND the patient remains afebrile for ≥48 hours. 3, 2, 1

• If a pathogen is identified: de-escalate to the most appropriate targeted antibiotic and continue until ANC >0.5 × 10⁹/L 3, 2
• If no pathogen is identified and ANC is recovering (>0.5 × 10⁹/L): continue antibiotics until afebrile ≥48 hours and ANC >0.5 × 10⁹/L 3, 2
• If no pathogen is identified and ANC remains <0.5 × 10⁹/L: 3, 2
  • Low-risk patients: complete 5–7 days of IV antibiotics
  • High-risk patients: continue IV antibiotics until ANC recovery

Persistent Fever (Beyond Day 4–7):

Add empiric antifungal therapy (voriconazole or liposomal amphotericin B) and obtain chest CT to evaluate for invasive fungal infection. 3, 2

• Reassess for: resistant organisms (MRSA, VRE, ESBL, KPC), fungal infection, non-infectious causes, inadequate source control 3, 2
• Consider galactomannan or β-D-glucan testing 3

---

Granulocyte Colony-Stimulating Factor (G-CSF)

G-CSF (filgrastim 5 µg/kg/day subcutaneously) is indicated for high-risk patients with expected prolonged neutropenia (>7 days). 1

• Initiate 24–72 hours after the last chemotherapy dose 1
• Continue until ANC >0.5 × 10⁹/L for two consecutive days 1
• CONTRAINDICATED during chest radiotherapy (associated with increased mortality) 1
• NOT routinely recommended for afebrile neutropenia or low-risk patients 1

---

Critical Pitfalls to Avoid

• Do NOT delay empiric antibiotics in febrile patients beyond the 2-hour window while awaiting culture results 3, 2, 1
• Do NOT withhold antibacterial prophylaxis in high-risk afebrile patients (expected neutropenia >7 days) 1
• Do NOT stop antibiotics prematurely in persistently neutropenic patients; therapy must continue until ANC recovery 3, 2, 1
• Do NOT add vancomycin empirically unless specific risk factors (catheter infection, MRSA colonization, hemodynamic instability) are present 3
• Do NOT use fluoroquinolone empiric therapy in patients already receiving fluoroquinolone prophylaxis 3
• Do NOT use G-CSF during active chest radiotherapy 1